Edgewise Therapeutics Inc at Bank of America Healthcare Conference Transcript
Thank you so much for being here today. Now we have the team from Edgewise Therapeutics which is developing precision therapies for rare muscle disorders.
So, without further ado, I'm going to pass the podium to Kevin Koch who is the CEO of Edgewise Therapeutics, and Behrad Derakhshan who is the Chief Business Officer.
Thank you. So thanks for attending today and we've got a really exciting story about our company.
And you know, what we are -- we started the company, it was really based on an observation that -- from back in the 1980s, that a certain type of muscle was degrading more readily than other types of muscles in muscular dystrophy patients. And that if you could regulate the damage to that muscle, you would have a profound effect on the disease.
So muscular dystrophy is a disease where you have a key structural protein called dystrophin, which is missing in the case of Duchenne muscular dystrophy, or a mutated and in diminished amounts in Becker
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
